The Pacific Islands conjures pictures of swaying palm trees and unspoiled beaches. But, after civil wars and unrest since the 1980’s, experts in the region are clear that Pacific Islanders cannot afford to be complacent about the future, even after almost a decade of relative peace and stability. And preventing conflict goes beyond ensuring law […]
LOS ANGELES, CA—(Marketwired – Jan 28, 2016) – Marathon Patent Group, Inc. (
In a pre–trial conference held Wednesday, January 27, 2016, Judge David E. Peebles scheduled a two–week trial to begin on May 2, 2016 for Rensselaer Polytechnic Institute and Dynamic Advances LLC v. Apple Inc., case number 1:13–cv–00633.
The suit involves Rensselaer Polytechnic Institute's (“RPI”) US Patent 7,177,798 ('798 patent), entitled “Natural language interface using constrained intermediate dictionary of results.” Dynamic Advances is the exclusive licensee of RPI's '798 patent.
On January 20, 2015, the Court issued its redacted public order denying all of the parties' pending motions, including Apple's motion for summary judgment and Apple's motion to exclude Plaintiffs' damages expert report. The Court's order included the following findings:
“The analytical approach, which has been endorsed by the Federal Circuit, 'attempts to place a quantitative value on benefits derived from the use of the patented technology[.]' Dkt. No. 211–3 at 39; see also Lucent Techs., Inc., 580 F.3d at 1324 (“[T]he analytical method focuses on the infringer's projections of profit for the infringing product.”). Mr. Yerman has calculated plaintiffs' damages, in the event a factfinder concludes Apple has infringed the '798 Patent, utilizing the analytical model, to be $429 million. Dkt. No. 211–3 at 42.”
“The hypothetical negotiation analysis represents a more traditional method of proving damages, giving consideration to the fifteen well–established Georgia–Pacific economic factors, and attempts to predict the 'appropriate reasonable royalty for allegedly infringing sales or uses made of the patented inventions' based on a hypothetical negotiation between the parties for a license under the '798 Patent. Dkt. No. 211–3 at 37; see also Lucent Techs., Inc., 580 F.3d at 1324 (“The second, more common approach, called the hypothetical negotiation or the 'willing licensor–willing licensee' approach, attempts to ascertain the royalty upon which the parties would have agreed had they successfully negotiated an agreement just before infringement began.”). As a result of his analysis under the hypothetical negotiation approach, Mr. Yerman concludes that an appropriate damage award, in the event infringement is proven, would be between $175 and $200 million.”
Both damages estimates are for the period from October 2011 through September 2014. It is expected that this number will be updated to account for Apple's alleged infringement from October 2014 to start of the trial in May 2016.
About Marathon Patent Group:
Marathon is a patent acquisition and monetization company. The Company acquires patents from a wide–range of patent holders from individual inventors to Fortune 500 companies. Marathon's strategy of acquiring patents that cover a wide–range of subject matter allows the Company to achieve diversity within its patent asset portfolio. Marathon generates revenue with its diversified portfolio through actively managed concurrent patent rights enforcement campaigns. This approach is expected to result in a long–term, diversified revenue stream. To learn more about Marathon Patent Group, visit www.marathonpg.com.
About Skiermont Derby LLP:
Paul J. Skiermont, founding partner of Skiermont Derby LLP, is lead trial counsel for Plaintiffs RPI and Dynamic Advances in their case against Apple. Skiermont Derby LLP is a trial boutique with offices in Dallas and Los Angeles, and was recently recognized in the national legal news publication Law360 as one of the top 10 boutique practices in the U.S. that are “on par with the biggest firms.” The firm represents plaintiffs and defendants in high stakes intellectual property and commercial litigation. To learn more about Skiermont Derby LLP, visit http://skiermontderby.com.
Safe Harbor Statement:
Certain statements in this press release constitute “forward–looking statements” within the meaning of the federal securities laws. Words such as “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “predict,” “forecast,” “project,” “plan,” “intend” or similar expressions, or statements regarding intent, belief, or current expectations, are forward–looking statements. While the Company believes these forward–looking statements are reasonable, undue reliance should not be placed on any such forward–looking statements, which are based on information available to us on the date of this release. These forward looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company's filings with the Securities and Exchange Commission (the “SEC”), not limited to Risk Factors relating to its patent business contained therein. Thus, actual results could be materially different. It is possible that Apple will prevail in the pending litigation. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.
The Paris climate change agreement adopted at the end of 2015 has put renewable energy at the heart of global energy system with investments expected to grow further even amidst the decline in fossil fuels. This was observed by delegates to the sixth International Renewable Energy Agency (IRENA) assembly held in Abu Dhabi, United Arab […]
NEW YORK, NY—(Marketwired – January 27, 2016) –
– Exhibition on view from Wednesday, February 24th to Thursday, March 31st. The Opening Reception will take place on Wednesday, March 9th from 6 to 8 pm.
– Artwork by contemporary artists Ran Hwang and Aimee Lee to be featured in the exhibition
– Special hanji making seminar and hands–on workshop by Aimee Lee on Saturday, March 12th and Sunday, March 13th
Celebrating 1000 years of the rich history of hanji, Korean traditional handmade paper, the Korean Cultural Center New York presents a feature exhibition of hanji
artworks by contemporary artists Ran Hwang and Aimee Lee in Re:visioning HANJI.
Hanji literally means 'the paper of Hanguk (the Korean term to refer to the country),' and is the exquisite traditional Korean paper made with the fibrous skin of mulberry trees. The process of making hanji
is lengthy and complicated, and it is said the completion of a single sheet of hanji requires “ninety–nine touches by the maker and one touch by the user.” The deliberate complexity and multilayered steps required for the creation of hanji is not only a direct reflection of its rich history but also contributes to its longstanding allure. In its respect of nature in the production process, its unmatched resilience and textural range, and the ways that hanji
has so closely been intertwined with the livelihood of Koreans (not only for as paper for drawing and writing but in the creation of everyday, household products), hanji has been an indispensible part of Korean history.
The exhibition explores the past, present, and future of hanji — from its long history since the 4th and 5th centuries in the Korean peninsula to the visually and texturally intricate artworks and industrial application in our contemporary times, Re:visioning HANJI is a celebration of the deep tradition and continuing potential of hanji
in the global market.
The participating artist, Ran Hwang, is an internationally renowned poetic installation artist who uses thousands of handmade hanji
buttons to create large–scale installation works. Hwang's 9 feet tall installation depicting the Triumphal Arch and Eiffel Tower will be shown at the exhibition. The installation, the Beginning of the Bright, is made of Hangul (Korean alphabet) shaped hanji
buttons to celebrate Hangul's designation as a UNESCO Record Cultural Heritage. Aimee Lee
is a hanji
educator, artist, and a founder of the first and only Korean papermaking studio in North America at the Morgan Conservatory in Cleveland. The exhibition will display diverse range of Lee's artworks from woven hanji ducks to hanji dresses and more.
Further detailed information and materials on the history, materials, and applications of hanji can be viewed and downloaded at our website at www.koreanculture.org
Partnered Event: HANJI Workshop
A weekend hanjiÂ workshop will be held on Saturday, March 12th and Sunday, March 13th at the Korean Cultural Center New York led by artist Aimee Lee, one of the leading hanji
experts in the United States. The workshops provide an in–depth and hands–on opportunity to learn about the nuanced process of making hanji, and also is a great chance to make your own hanji
The program is free, but reservations are required and space is limited. Please note that programs on March 12th and 13th differ, and level of difficulty should be noted. For more information on the workshop, please email email@example.com
Aimee LeeÂ is papermaking artist and the leading hanji researcher and practitioner in the United States. She holds a BA from Oberlin College and an MFA from Columbia College Chicago. She researched Korean paper arts as a Fulbright fellow and built the first and only Korean papermaking studio in North America in 2010 at the Morgan Conservatory in Cleveland. In 2012, The Legacy Press published her first book,Â Hanji Unfurled: One Journey into Korean Papermaking, recognized by the Eric Hoffer Book Award in 2013.Â
Based on Korean gifting and hanji traditions, Aimee Lee's Hanji DucksÂ and Pot series are 100% hanji, woven and naturally dyed in varied dimensions, gestures, and environments. Lee says, “my pieces examine traditional objects used in various moments of life and history: paper shoes, once in vogue during the last dynasty in Korea; wedding ducks given to bride and groom to encourage fidelity and fertility; and water or wine gourds to store and improve the taste of beverages while traveling. I alter these forms by changing their proportions, shapes, and pairings to see how older technologies and stories inform contemporary versions of objects we use to this day.”
Lee exhibits internationally, and her artists' books reside in collections that include the Joan Flasch Artists' Books Collection, Museum of Modern Art Library, and Yale University Haas Library. She teaches and lectures at sites that include the American Museum of Natural History, Asian Art Museum, Cleveland Museum of Art, Denver Art Museum, Cleveland Institute of Art, Institute of East Asian Studies at UC Berkeley, Metropolitan Museum of Art Paper Conservation Department, Oberlin College, Massachusetts College of Art and Design, Mills College, Notre Dame College, UC Davis, UW Seattle, University of the Arts, University of Iowa Center for the Book, Center for Book Arts, Peters Valley School of Craft, Penland School of Crafts, and North Bennett Street School. She has been a resident artist at Art Farm, Jentel, GuapamacÃ¡taro Center for Art and Ecology, Haystack, Ox–Bow, Ragdale, Saltonstall Arts Colony, Santa Fe Art Institute, Vermont Studio Center, and Weir Farm Arts Center. Funders include the US Fulbright Program, Korea Fulbright Foundation, New York Foundation for the Arts Special Opportunity Stipend Program, John Anson Kittredge Fund, American Folklore Society, Manhattan Graphics Center, and the Puffin Foundation.
Ran Hwang creates monumental iconic imagery by using materials from the fashion industry: buttons (made of hanji), thread, and beads. Born in Busan, South Korea, Hwang moved to the United States in 1997 to further her artistic studies. She studied Fine Arts at the School of Visual Arts in New York City and attended the Graduate School of Fine Arts at Chung–Ang University in Seoul.
Ran Hwang's the Beginning of the Bright
is a triptych installation which displays over 100,000 handmade hanji buttons on 86.6 inches wide Plexiglas panels. To construct her work, Hwang handmade hanji buttons and hammered each on pins approximately twenty–five times until secured. Hwang says her work is a form of meditative ritual, similar to the the meditative practices by Zen masters as her work requires labor–intensive process and utmost concentration.
Ran Hwang is currently works and lives in New York City and Seoul. She has exhibited at several international institutions including the Queens Museum of Art, the UNESCO Paris Headquarters, the MASS MoCA, International Museum of Art and Science, the Third Floor–HermÃ¨s, and the Seoul Arts Center Museum. Hwang's works are held in esteemed public and private collections including the Pullman Kaifeng Hotel, Four Seasons Hotel, Royal Caribbean International Anthem of the Seas AFT Wall Art, Third Floor–HermÃ¨s, King County Library in Issaquah, Des Moines Art Center, the Brooklyn Museum, New York Plaza Hotel, National Museum of Contemporary Art, and Hammond Museum.
The Re:visioning HANJI exhibition is presented in part with the 2016 Asia Week New York and in its mission “to promote Asian art in New York City [in collation with] top–tier Asian art specialists, major auction houses, and world renowned museums” including the Metropolitan Museum of Art, the Museum of Modern Art, Sotheby's, and Christie's auction house among many others.
About the Korean Cultural Center New York
Inaugurated in 1979, the Korean Cultural Center New York is a branch of the Ministry of Culture, Sports and Tourism (MCST) of the Republic of Korea. Under the authority of the Consulate General of the Republic of Korea in New York, the Korean Cultural Center works to promote cultural arts exchange and stimulate interest in Korean culture through various opportunities. The Korean Cultural Center provides diverse activities including exhibitions, concerts, film festivals, and educational programs. The Korean Cultural Center New York is located at 460 Park Avenue (at 57th Street), 6th Floor, New York City. www.koreanculture.org
The following files are available for download:
MARKHAM, ON—(Marketwired – January 27, 2016) – LEO Pharma, Denmark's oldest healthcare company, announced today the launch of its first innovation lab in North America. Backed by $100M CDN in funding, LEO Innovation Lab will develop new, non–pharmaceutical solutions for people living with psoriasis and partner with the startup community to foster innovation in apps, web platforms, wearables, virtual reality, artificial intelligence, tele–medicine and other advanced technologies.Â Located north of Toronto in Markham, LEO Innovation Lab is LEO Pharma's first innovation venture outside of Europe. Similar innovation labs today operate in Copenhagen, London and Paris.
Psoriasis affects approximately 125 million people worldwide. According to a recent patient survey, psoriasis and related conditions 'impose a severe burden on the daily lives of individuals,' and quality of life for those suffering from the condition is a major cause for concern.
“We know that psoriasis affects many aspects of daily life beyond ones that can be treated with medication,” said Miron Derchansky, Head of LEO's Innovation Lab in Toronto.Â “LEO Pharma has been developing pharmaceutical products since 1908, and now we're turning to the digital space and the startup community to help us hack new and creative solutions to help people better manage and deal with their condition.”
LEO Innovation Lab will focus on areas such as stress, diet, social relationships and healthcare provider interaction. LEO Canada's CEO, Xavier Bertin, in partnership with Miron Derchansky will ensure the ideas generated in the Innovation Lab are tested in the Canadian marketplace:Â “We are very proud to be a key country involved in this global initiative. It fits perfectly with our long term commitment to help people suffering from skin disease to live a better life,” says Bertin.
Through its newly announced LEO Ventures initiative, LEO Innovation Lab is also prepared to invest in and give grants to startups to help contribute to finding and developing solutions. The LEO Innovation Lab itself has been established with non profit requirements and is part of a long–term strategic decision by LEO Pharma to put people at the centre, even if there is no immediate financial gain from doing so, explains Gitte Aabo, CEO of LEO Pharma and member of LEO Innovation Lab's board.
“This does not mean that we perceive helping people as a contradiction to driving a sustainable business. In LEO Pharma, we do not help patients in order to make money; we make money in order to help patients,” says Aabo.
Facts about LEO Innovation Lab
â Â New innovation lab with 100 million CAD in funding and no profit requirements
â Â Does not develop pharmaceutical products, but offers a wide range of other solutions to improve life of people living with psoriasis
â Â The timeframe for projects will be 100 days from ideation to beta test
â Â Independently operating unit with its own board with key performance metrics focused on making a difference for people living with psoriasis
â Â Established by LEO Pharma as part of a long–term strategic decision to put people at the centre
â Â LEO Pharma is owned by the LEO Foundation and profits are reinvested in the company
 Canadian Dermatology Association “Living with Psoriasis” http://www.dermatology.ca/skin–hair–nails/skin/psoriasis/living–with–%20psoriasis/
With El Nino affecting countries in southern Africa, threatening agricultural production due to a massive heat wave, the World Food Programme has urged the international community to support the upscaling of climate smart agricultural technology for resilience. During her recent visit to Zambia, one of the region’s foremost producers and exporters of maize and other […]
Porter Ngengh Tike is in her late thirties, but looks well over 50. For 8 hours every day, she carries around a large bamboo basket on her head, delivering supplies to local traders in the biggest traditional market of Bali – Pasar Badung. At the end of the week, she earns about 18 dollars – […]
FAIRFAX, VA—(Marketwired – January 26, 2016) – A phase 1 trial examining precision hypofractionated radiation therapy (RT) in locally advanced non–small cell lung cancer (NSCLC) cases found that higher RT doses in a shorter time span were potentially cost–effective and generally well tolerated, while allowing for fewer radiation treatments. The study, “Precision hypofractionated radiation therapy in poor performing patients with non–small cell lung cancer: Phase 1 dose escalation trial,” was published in the International Journal of Radiation Oncology – Biology – Physics (Red Journal), the official scientific journal of the American Society for Radiation Oncology (ASTRO).
“Advanced radiotherapy technology, although requiring resources to acquire and thoughtful physician/staff training to operate, can lead to improvements in patient care and outcome, giving hope to even the most frail, at–risk, cancer patients,” said lead author Robert Timmerman, MD, University of Texas Southwestern Medical Center at Dallas (UTSW). “And, somewhat surprisingly, this approach is shown to be very cost effective, which is welcomed in this era of difficult–to–control medical expenditures.”
The trial was conducted at UTSW and Stanford University Medical Center. Kenneth D. Westover, MD, PhD, also at UTSW, is first author on the study.
The standard of care in NSCLC cases is concurrent chemoradiation, with an absolute survival benefit of 4 percent to 7 percent at 5 years compared to sequential chemotherapy and RT, the study authors reported. Patients experiencing medical comorbities or cancer–associated decline cannot always receive concurrent chemoradiation treatment because side effects negate potential benefits. For those patients, hypofractionated RT is another option, study authors said. However, its past use has been fraught with the limitations of older technology, with shortened treatments causing excessive toxicity. The current study was designed to examine the use of hypofractionation with modern, advanced radiotherapy planning and delivery technologies including image guidance, intensity modulation and adaptation.
“It was previously shown that patients with earlier stages of lung cancer could have very effective treatment completed in fewer than five non–invasive treatments by using more modern, advanced and precise technology to direct the beams,” Dr. Timmerman said. “We specifically tested this novel therapy in the frailest patients, the so–called poor–performing patients, who are usually not allowed into clinical trials.”Â
The study examined 55 patients with stage II to IV or recurrent NSCLC and Eastern Cooperative Oncology Group performance status of 2 or greater who were not candidates for surgical resection, stereotactic radiation or concurrent chemoradiation. Median age was 70 years old. Sixty–seven percent of patients were male. Seventy percent had a greater than or equal toÂ 30 pack–year smoking history. Tumors in this patient population were large, on average, and commonly localized to the right upper lobe. Approximately 25 percent of patients were stage IV, and the majority of patients were stage III.
The trial's primary endpoint was to determine the maximally tolerated dose (MTD), which was defined as “an unacceptable G3 or higher treatment–related, protocol–specified, adverse event (dose–limiting toxicities [DLT]), and defined according to Common Terminology Criteria for Adverse Events v.3.0.” MTD was exceeded if 33 percent of evaluable patients experienced DLTs in the time measured.
In the study, highly conformal radiation therapy was used in 15 fractions to a total of 50, 55 or 60Gy doses. Of the 55 patients, 15 received 50Gy dose level treatment, 21 received 55Gy dose level treatment and 19 received 60Gy dose level treatment. Of those, the 60Gy arm had the most stage IV disease, at 32 percent, but the amount was not statistically significant.
Study subjects had to experience a treatment–related DLT or survive 90 days to be evaluable. Doses were escalated when the last patient enrolled to that dose level had completed a minimum of 90 days' follow–up without experiencing a DLT.
Patients were permitted to undergo chemotherapy after radiation, per consultation with a treating physician.
A 90–day follow–up was completed in all three dose level treatment groups without exceeding the MTD. Because the MTD was not reached, it could be possible that higher doses, according to the definition of the trial, might also be safe, study authors said.
The median follow–up was 12.5 months. At that point, 93 grade of greater than or equal toÂ 3 adverse events had occurred, including 39 deaths. Most of the adverse events were considered related to factors other than radiation therapy. Median overall survival was 6 months with no significant differences between dose levels (P=.59).
Study authors found that results could suggest that a hypofractionated regime is safely delivered with photons rather than particle therapy or other specialized techniques, which could have implications for resource allocation.
They also reported that the potential in cost savings from the reduced treatment schedule could be an added benefit of a hypofractionated regime. The current duration of standard RT in locally advanced lung cancer cases is 30–40 treatments for six to eight weeks, compared to the 15 treatments administered over three weeks in this study.
Â Older patients have lower survival rates, which could be connected to not receiving therapy at the same rate as younger patients, study authors reported. Hypofractionated RT could benefit these patients because it would provide them with well tolerated RT over a shorter timeline.
“Providing a therapy that is tolerable in this population may reduce this age disparity in survival outcomes, although it remains to be seen whether the increased potency of hypofractionated RT approaches the potency regimens of concurrent chemoradiation for controlling locally advanced disease,” study authors said.
Dr. Timmerman said a larger trial comparing these results to standard combined chemotherapy and radiotherapy is needed.
“We have already instigated a larger, randomized trial to compare the new 15 treatment regimen to conventional radiation using 30 treatments,” he said. “Depending on the results, a trial comparing the new high–tech, yet cost–effective, therapy to standard chemo–radiotherapy in better performing patients should be considered.”
For more information, contact ASTRO's Press Office at firstname.lastname@example.org. For the study, visit http://www.redjournal.org/article/S0360–3016(15)00505–2/abstract. For more information about
Red Journal, visit http://www.redjournal.org.Â
ASTRO is the premier radiation oncology society in the world, with more than 10,000 members who are physicians, nurses, biologists, physicists, radiation therapists, dosimetrists and other health care professionals that specialize in treating patients with radiation therapies. As the leading organization in radiation oncology, the Society is dedicated to improving patient care through professional education and training, support for clinical practice and health policy standards, advancement of science and research, and advocacy.Â ASTRO publishes three medical journals, International Journal of Radiation Oncology – Biology – Physics (www.redjournal.org), Practical Radiation Oncology (www.practicalradonc.org) and Advances in Radiation Oncology (www.advancesradonc.org); developed and maintains an extensive patient website, RT Answers (www.rtanswers.org); and created the Radiation Oncology Institute (www.roinstitute.org), a nonprofit foundation to support research and education efforts around the world that enhance and confirm the critical role of radiation therapy in improving cancer treatment. To learn more about ASTRO, visit www.astro.org.
FORT WASHINGTON, PA—(Marketwired – January 26, 2016) – It is estimated that more than 5,000 cases of Vulvar Cancer were diagnosed in the United States in 2015, and approximately 1,000 women died from the disease[i]. In order to provide comprehensive, up–to–date clinical treatment guidelines for this rare cancer, the National Comprehensive Cancer NetworkÂ® (NCCNÂ®), an alliance of 26 of the nation's leading cancer centers, has published the NCCN Clinical Practice Guidelines in Oncology (NCCN GuidelinesÂ®) for Vulvar Cancer. The new NCCN GuidelinesÂ® for Vulvar Cancer provide recommendations on the evaluation and treatment of squamous cell carcinoma of the vulva and include principles of surgery, principles of radiation therapy, and systemic therapy.
NCCN Guidelines document evidence–based consensus–driven management to ensure that all patients receive preventive, diagnostic, treatment, and supportive services that are most likely to lead to optimal outcomes.
“The creation of these new guidelines represents a multidisciplinary effort to codify appropriate standards of care for patients with vulvar cancer, based on available published evidence and contemporary patterns of practice,” said Wui–Jin Koh, MD, Professor of Radiation Oncology, Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance, and Co–Chair, NCCN Guidelines Panel for Vulvar Cancer.
“These guidelines are essential to establish a standard of care for this rare disease, and serve as a platform for future investigations and improved outcomes,” said Benjamin E. Greer, MD, Director of Gynecological Cancer, Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance, and Co–Chair, NCCN Guidelines Panel for Vulvar Cancer.
With the publication of the NCCN Guidelines for Vulvar Cancer, the library of NCCN Guidelines now includes 62 clinical guidelines detailing sequential management decisions and interventions that currently apply to 97 percent of cancers affecting people in the United States, as well as cancer prevention, detection and risk reduction, and age–related recommendations.
Available free–of–charge to registered users of NCCN.org and through the Virtual Library of NCCN Guidelines Mobile Apps, NCCN Guidelines document evidence–based, consensus–driven management to help oncologists make the major clinical decisions encountered in managing their patients by providing ready access to synthesized information. The NCCN Guidelines provide recommendations for appropriate care for most, but not all patients; however, individual patient circumstances must be considered when applying these recommendations.
To access the NCCN Guidelines for Vulvar Cancer, visit NCCN.org.
About the National Comprehensive Cancer Network
The National Comprehensive Cancer NetworkÂ® (NCCNÂ®), a not–for–profit alliance of 26 of the nation's leading cancer centers devoted to patient care, research, and education, is dedicated to improving the quality, effectiveness, and efficiency of cancer care so that patients can live better lives. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. As the arbiter of high–quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision–makers.
The NCCN Member Institutions are: Fred & Pamela Buffett Cancer Center, Omaha, NE; Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; City of Hope Comprehensive Cancer Center, Los Angeles, CA; Dana–Farber/Brigham and Women's Cancer Center | Massachusetts General Hospital Cancer Center, Boston, MA; Duke Cancer Institute, Durham, NC; Fox Chase Cancer Center, Philadelphia, PA; Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT; Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance, Seattle, WA; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL; Mayo Clinic Cancer Center, Phoenix/Scottsdale, AZ, Jacksonville, FL, and Rochester, MN; Memorial Sloan Kettering Cancer Center, New York, NY; Moffitt Cancer Center, Tampa, FL; The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute, Columbus, OH; Roswell Park Cancer Institute, Buffalo, NY; Siteman Cancer Center at Barnes–Jewish Hospital and Washington University School of Medicine, St. Louis, MO; St. Jude Children's Research Hospital/The University of Tennessee Health Science Center, Memphis, TN; Stanford Cancer Institute, Stanford, CA; University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, AL; UC San Diego Moores Cancer Center, La Jolla, CA; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; University of Colorado Cancer Center, Aurora, CO; University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; The University of Texas MD Anderson Cancer Center, Houston, TX; Vanderbilt–Ingram Cancer Center, Nashville, TN; and Yale Cancer Center/Smilow Cancer Hospital, New Haven, CT.
[i] “Cancer Facts & Figures 2015.” American Cancer Society. Web. 12 Jan. 2016.
The following files are available for download:
ROSELAND, NJ—(Marketwired – Jan 26, 2016) – ADP (
But exactly what are Private Exchanges, and how do employers know what to look for when selecting one? What are the benefits of a Private Exchange and how can companies determine if it would be the right approach for their business?
To help employers better understand the role Private Exchanges can play in their overall benefits strategy, this panel discussion will address:
- The types of Exchange models available in the market;
- The current and anticipated growth rates of Exchanges;
- The types of businesses that have been early adopters and why;
- The benefits and risks of different funding models;
- What to look for when evaluating an Exchange model;
- The role of user experience and decision support in employee engagement; and
- Emerging trends.
This free webinar will begin at 11 a.m. ET on Tuesday, February 2, and will feature a panel discussion with Gerry Leonard, President of ADP Benefits Services, Arthur Hall, Senior Vice President – National Practice Leader Employee Benefits at USI, and Doug Field, CEO and founder of The Institute for HealthCare Consumerism.
Register here and learn more at HR.com.
About ADP (
Powerful technology plus a human touch. Companies of all types and sizes around the world rely on ADP's cloud software and expert insights to help unlock the potential of their people. HR. Talent. Benefits. Payroll. Compliance. Working together to build a better workforce. For more information, visit ADP.com.
The ADP logo and ADP are registered trademarks of ADP, LLC. ADP A more human resource. is a service mark of ADP, LLC. All other marks are the property of their respective owners. Copyright © 2016 ADP, LLC.